Positive Health Online
Your Country
![[Image: http://www.abundanceandhealth.co.uk]](/img/original/BannerAvatar/2836.df7d2315253110ff5b3a566f94871f99.jpg "http://www.abundanceandhealth.co.uk")
![[Image: http://www.balens.co.uk]](/img/original/BannerAvatar/2148.50367fa908013fae0a7f1a171543ef92.jpg "http://www.balens.co.uk")
![[Image: https://www.water-for-health.co.uk/]](/img/original/BannerAvatar/4046.12831f50177f8848ee87b8e94411d6b3.jpg "https://www.water-for-health.co.uk/")
![[Image: http://www.drsgoodman.com/books-goodman/52-nutrition-and-cancer]](/img/original/BannerAvatar/1859.1296090fd8385e7ceff51c8011559097.jpg "http://www.drsgoodman.com/books-goodman/52-nutrition-and-cancer")
Research: EVANS and COLLEAGUES,
Listed in Issue 170
Abstract
EVANS and COLLEAGUES, Department of Clinical Sciences, Clinical Research Center, Lund University, University Hospital, 205 02, Malmo, Sweden tested the anticancer effect of TBS-101, a newly developed anti-cancer botanical in the treatment of prostate cancer.
Background
Traditional Botanical Supplement-101 (TBS-101) is a newly developed proprietary botanical agent containing seven standardized botanical extracts, including: Panax ginseng, cranberry, green tea, grape skin, grape seed, Ganoderma lucidum and chamomile. Each of the components has been consumed either in the regular diet or as natural supplement. When used as a single agent, each of these seven botanicals has been implicated in chemoprevention and therapy in various types of cancer. The anticancer effect of TBS-101, with the specific combination of these anti-cancer botanicals for the treatment of prostate cancer (PCa), has not been tested.
Methodology
The IC(50) and the effect of TBS-101 on the proliferation and apoptosis of PC-3 cells were determined. Tumour xenograft mice were generated by subcutaneously implanting PC-3 cells into mice and tumours were allowed to grow to different sizes before starting the treatment. The effects of TBS-101 on tumour growth were assessed by measuring tumour size and by histological, pathological and immunohistochemical analyses. A basic toxicity study was performed to test the tolerance of the mice to high doses of TBS-101.
Results
Treatment of the PC-3 cells with TBS-101 resulted in a dose-dependent inhibition of cell growth, with an IC(50) of 1.4 microg/ml. A concomitant induction of apoptosis in PC-3 cells treated with TBS-101 was also observed. Upon the treatment with TBS-101, all three groups of mice bearing moderate or large tumours showed significant inhibition of tumour growth and invasion. In contrast, control mice treated with vehicle alone had significant tumour growth and lymph node metastasis. In the basic toxicity studies, high doses of TBS-101 exerted no toxicity in healthy or tumour-bearing mice.
Conclusion
The natural botanical agent TBS-101 has a good safety profile and significant anticancer activities in hormone-refractory PC-3 cells and large aggressive PC-3 tumours in a xenograft mouse model and has great potential for the treatment of aggressive prostate cancer.
References
Evans S, Dizeyi N, Abrahamsson PA and Persson J. The effect of a novel botanical agent TBS-101 on invasive prostate cancer in animal models. Anticancer Research 29 (10): 3917-24. Oct 2009.
Comment
The seven herbs by themselves have shown significant antioxidant and immune enhancement effects. The results of the Botanical Supplement showed dose-dependent inhibition of cell growth, as well as the induction of apoptosis. This compared with the controls who showed significant tumour growth and lymph node metastasis. This could be good news in the treatment and prevention of aggressive prostate cancer.
